Acquired Resistance of EGFR-Mutant Lung Adenocarcinomas to Afatinib plus Cetuximab Is Associated with Activation of mTORC1-Reference-Cited by-同舟云学术

Acquired Resistance of EGFR-Mutant Lung Adenocarcinomas to Afatinib plus Cetuximab Is Associated with Activation of mTORC1

Published:2014-05 Issue:4 Volume:7 Page:999-1008
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Pirazzoli Valentina,Nebhan Caroline,Song Xiaoling,Wurtz Anna,Walther Zenta,Cai Guoping,Zhao Zhongming,Jia Peilin,de Stanchina Elisa,Shapiro Erik M.,Gale Molly,Yin Ruonan,Horn Leora,Carbone David P.,Stephens Philip J.,Miller Vincent,Gettinger Scott,Pao William,Politi Katerina

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference20 articles.

1. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling;Chmielecki;Sci. Transl. Med.,2011

2. Contact-dependent inhibition of EGFR signaling by Nf2/Merlin;Curto;J. Cell Biol.,2007

3. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing;Frampton;Nat. Biotechnol.,2013

4. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth;James;Mol. Cell. Biol.,2009

5. Activity of afatinib/cetuximab in patients with EGFR mutant non-small cell lung cancer and acquired resistance to EGFR inhibitors;Janjigian;Ann. Oncol.,2012

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TRKing down drug resistance in NTRK fusion‐positive cancers^†;The Journal of Pathology;2024-07-29

2. Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer;Nature Communications;2024-07-19

3. Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivoLMNA::NTRK1‐rearranged soft‐tissue sarcoma cell model;The Journal of Pathology;2024-04-12

4. Preclinical Modeling of Pathway-Targeted Therapy of Human Lung Cancer in the Mouse;Cold Spring Harbor Perspectives in Medicine;2023-10-03

5. Inhibition of a lower potency target drives the anticancer activity of a clinical p38 inhibitor;Cell Chemical Biology;2023-10